Shell Asset Management Co. Sells 999 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Shell Asset Management Co. cut its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 12.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,745 shares of the biotechnology company’s stock after selling 999 shares during the quarter. Shell Asset Management Co.’s holdings in Blueprint Medicines were worth $431,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. boosted its position in Blueprint Medicines by 19.8% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 906 shares of the biotechnology company’s stock worth $97,000 after buying an additional 150 shares during the period. CIBC Asset Management Inc boosted its position in Blueprint Medicines by 7.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,536 shares of the biotechnology company’s stock worth $272,000 after buying an additional 168 shares during the period. State of New Jersey Common Pension Fund D boosted its position in Blueprint Medicines by 0.5% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 35,131 shares of the biotechnology company’s stock worth $3,763,000 after buying an additional 175 shares during the period. Van ECK Associates Corp boosted its position in Blueprint Medicines by 15.2% during the 4th quarter. Van ECK Associates Corp now owns 1,335 shares of the biotechnology company’s stock worth $143,000 after buying an additional 176 shares during the period. Finally, Exane Derivatives boosted its position in Blueprint Medicines by 45.8% during the 1st quarter. Exane Derivatives now owns 567 shares of the biotechnology company’s stock worth $36,000 after buying an additional 178 shares during the period. 99.69% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BPMC has been the topic of several recent research reports. The Goldman Sachs Group lifted their target price on shares of Blueprint Medicines from $126.00 to $143.00 and gave the stock a “buy” rating in a research report on Wednesday. Raymond James restated a “maintains” rating on shares of Blueprint Medicines in a research report on Wednesday. JMP Securities restated a “buy” rating and issued a $152.00 price target on shares of Blueprint Medicines in a research report on Thursday, June 9th. Stifel Nicolaus dropped their price target on shares of Blueprint Medicines from $98.00 to $90.00 in a research report on Friday, July 1st. Finally, Morgan Stanley dropped their price target on shares of Blueprint Medicines from $92.00 to $65.00 and set an “equal weight” rating on the stock in a research report on Tuesday, June 14th. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $92.67.

Blueprint Medicines Stock Up 6.1 %

NASDAQ:BPMC opened at $59.70 on Thursday. The company has a fifty day moving average of $53.74 and a 200-day moving average of $61.42. The firm has a market capitalization of $3.56 billion, a P/E ratio of -5.40 and a beta of 0.94. Blueprint Medicines Co. has a twelve month low of $43.46 and a twelve month high of $117.86.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported ($2.68) EPS for the quarter, missing analysts’ consensus estimates of ($2.23) by ($0.45). The business had revenue of $36.55 million for the quarter, compared to the consensus estimate of $37.61 million. Blueprint Medicines had a negative net margin of 293.97% and a negative return on equity of 35.24%. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.86) EPS. On average, analysts anticipate that Blueprint Medicines Co. will post -7.75 EPS for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Percy H. Carter sold 1,908 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $59.76, for a total transaction of $114,022.08. Following the completion of the sale, the insider now owns 28,685 shares in the company, valued at approximately $1,714,215.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.34% of the stock is currently owned by company insiders.

Blueprint Medicines Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Featured Stories

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Want More Great Investing Ideas?

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.